1. Home
  2. ICUI vs NAMS Comparison

ICUI vs NAMS Comparison

Compare ICUI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$146.10

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$32.69

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICUI
NAMS
Founded
1984
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.5B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
ICUI
NAMS
Price
$146.10
$32.69
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$182.25
$47.33
AVG Volume (30 Days)
272.9K
666.3K
Earning Date
05-22-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
100.62
N/A
EPS
0.03
N/A
Revenue
$2,231,262,000.00
N/A
Revenue This Year
N/A
$38.17
Revenue Next Year
$4.10
$573.62
P/E Ratio
$4,973.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$107.02
$14.06
52 Week High
$160.29
$42.00

Technical Indicators

Market Signals
Indicator
ICUI
NAMS
Relative Strength Index (RSI) 44.65 42.43
Support Level $142.11 $30.34
Resistance Level $151.64 $37.43
Average True Range (ATR) 6.67 1.82
MACD -0.34 -0.12
Stochastic Oscillator 28.86 5.46

Price Performance

Historical Comparison
ICUI
NAMS

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: